Cayman Bosutinib-d8

Bosutinib-d₈ is intended for use as an internal standard for the quantification of bosutinib (Item No. 12030) by GC- or LC-MS. Bosutinib is an inhibitor of c-Src and Abl kinases (IC₅₀s = 1.2 and 1 nM, respectively).^1,2 It also inhibits the kinases EPHB2, TrkA, TrkB, and TXK (IC₅₀s = 8.5, 22, 27, and 40 nM, respectively) among others.³ Bosutinib inhibits Src-dependent cell proliferation (IC₅₀ = 100 nM) and reverses Src-transformed fibroblasts to a non-transformed morphology when used at a concentration of 1 µM.¹ It reduces tumor growth in unstaged and staged Src-transformed fibroblast mouse xenograft models when administered at doses of 30 or 25 mg/kg, respectively, twice per day. Bosutinib (100 mg/kg) also induces complete tumor regression in a K562 mouse xenograft model when administered once per day for five days.²

WARNING This product is not for human or veterinary use.